Methamphetamine-associated psychosis. Mental and behavioural disorders due to use of other stimulants, including caffeine
Conditions
Interventions
Intervention 1: Group 1 received Haloperidol (5 to 20 mg, per day) for 3 weeks. Intervention 2: Group 2 received Risperidone (2 to 8 mg, per day) for 3 weeks.
Treatment - Drugs
Group 1 received Haloperidol (5 to 20 mg, per day) for 3 weeks.
Group 2 received Risperidone (2 to 8 mg, per day) for 3 weeks.
Sponsors
Vice chancellor for research of University of Social Welfare and Rehabilitation Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patient in the age range 18 to 60; signing informed consent. Exclusion criteria: presence of other psychiatric disorders; abusing of other psycho stimulant drugs; comorbid neurological disorders; mental retardation.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Methamphetamine-associated psychosis. Timepoint: Baseline, the first week after intervention, the second week after intervention, the third week after intervention, the first week after finishing the intervention. Method of measurement: Scale of Assessment of Positive Symptoms (SAPS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Roya Samadi
Mashhad University of Medical sciences
Outcome results
None listed